高级检索
当前位置: 首页 > 详情页

CEBPB promotes transformation of endometrial complex atypical hyperplasia to endometrial cancer

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Kunming Univ Sci & Technol, Peoples Hosp Yunnan Prov 1, Affiliated Hosp, Dept Obstet & Gynecol, 157 Jinbi Rd, Kunming 650032, Peoples R China [2]Kunming Med Univ, Affiliated Hosp 2, Dept Urol, 374 Dianmian Ave, Kunming 650101, Peoples R China
出处:
ISSN:

关键词: Endometrial complex atypical hyperplasia Endometrial cancer Transformation CEBPB Biomarker

摘要:
BackgroundAs the precursor malignancy of endometrial cancer (EC), about 50% of endometrial complex atypical hyperplasia (CAH) will eventually progress to EC. Elucidating the underlying transformation mechanisms could aid in disease management.MethodsEC, CAH, reversed CAH and normal endometrium tissues were collected and sequenced to identify genes involved in the malignant transformation. CEBPB expression was then compared between endometrial CAH and normal endometrium. After evaluation of its effects on proliferation, apoptosis, EMT, migration and invasion by using primary culture, the promotion effects of CEBPB on endometrial CAH were further confirmed using RNA sequencing.ResultsBy integrating RNA sequencing data, CEBPB was identified as implicated in the transformation from endometrial CAH to EC. Endometrial CAH had overexpressed CEBPB compared with normal endometrium, but the expression decreased as the disease reversed. Primary cultures of CAH had enhanced proliferation, EMT, migration and invasion but reduced apoptosis compared with that of normal endometrium. Knockdown CEBPB in CAH primary cultures could suppress the proliferation, EMT, migration and invasion while increasing apoptosis, rendering the disease phenotype. Genes regulated by CEBPB were also significantly enriched in pathways related to the malignant transformation.ConclusionsCEBPB is involved in endometrial CAH and promotes the transformation from CAH to EC. CEBPB could potentially be exploited as a surrogate screening and surveillance biomarker for endometrial CAH at high cancerous risk, enabling better risk stratification and individualized treatment.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
JCR分区:
出版当年[2024]版:
Q2 ONCOLOGY
最新[2024]版:
Q2 ONCOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2023版]

第一作者:
第一作者机构: [1]Kunming Univ Sci & Technol, Peoples Hosp Yunnan Prov 1, Affiliated Hosp, Dept Obstet & Gynecol, 157 Jinbi Rd, Kunming 650032, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:91327 今日访问量:0 总访问量:773 更新日期:2025-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号 ICP备案:滇ICP备15003244号